

DIAGNÓSTICOS DA AMÉRICA S.A.
Publicly Held Company
Corporate Taxpayer ID (CNPJ/MF): 61.486.650/0001-83
Corporate Registry (NIRE): 35.300.172.507

MATERIAL FACT

MERGER OF WHOLLY-OWNED SUBSIDIARIES

DIAGNÓSTICOS DA AMÉRICA S.A. (“**DASA**” or the “**Company**”), in compliance with the provisions of CVM Resolution No. 44, dated August 23, 2021, and CVM Resolution No. 78, dated March 29, 2022 (“**CVM Resolution No. 78/22**”), hereby informs its investors and the market in general that, on March 26, 2026, the Company’s Board of Directors approved the execution of the following agreements: **(i)** the “Protocol and Justification for the Merger of Fernando Henriques Pinto Junior & Cia Ltda. into Diagnósticos da América S.A.” (“**Fernando Henriques Protocol and Justification**”); **(ii)** the “Protocol and Justification for the Merger of Aliança Biotecnologia Ltda. into Diagnósticos da América S.A.” (“**Aliança Protocol and Justification**”); and **(iii)** the “Protocol and Justification for the Merger of Instituto de Hematologia de S. J. R. Preto Ltda. into Diagnósticos da América S.A.” (“**Institute of Hematology Protocol and Justification**” and, together with the Fernando Henriques Protocol and Justification and the Aliança Protocol and Justification, the “**Protocols and Justifications**”).

The Protocols and Justifications, submitted together with the respective valuation reports and other relevant documents to the Company’s Board of Directors, set forth the terms and conditions for the merger into the Company of the following wholly-owned subsidiaries: (i) Fernando Henriques Pinto Junior & Cia Ltda. (“**FHPJ**” and “**FHPJ Merger**”, respectively); (ii) Aliança Biotecnologia Ltda. (“**Aliança**” and “**Aliança Merger**”, respectively); and (iii) Instituto de Hematologia de S. J. R. Preto Ltda. (“**Institute of Hematology**” and, together with FHPJ and Aliança, the “**Merged Companies**”; and “**Institute of Hematology Merger**” and, together with the FHPJ Merger and the Aliança Merger, the “**Mergers**”, respectively). Such matters will be submitted for resolution at the Company’s Ordinary and Extraordinary General Shareholders’ Meeting, to be held at 2:00 p.m. on April 28, 2026, in an exclusively digital format.

Pursuant to the provisions of Article 3 of CVM Resolution No. 78/22, the Company sets forth below the main terms, conditions and other relevant information relating to the Mergers, in accordance with the provisions of the respective Protocols and Justifications.

1. Identification of the Companies Involved and Summary of Their Respective Activities

DASA: The Company is a publicly-held corporation, headquartered in the City of Barueri, State of São Paulo, at Avenida Juruá, No. 434, Alphaville, ZIP Code 06455-010, enrolled with the Brazilian Corporate Taxpayer Registry (CNPJ/MF) under No. 61.486.650/0001-83. The Company’s corporate purpose includes:

- (i)** the provision of auxiliary diagnostic support services (ADS) to private patients or through accredited companies, insurance companies, medical-hospital assistance entities, and other healthcare funding arrangements, including clinical analyses and vaccination services, whether provided directly or on

a supplementary basis through contracted laboratories; as well as other auxiliary diagnostic support services (ADS), provided exclusively through specialized medical companies, for example in the following areas: (a) cytology and anatomical pathology; (b) diagnostic imaging and graphic methods; and (c) nuclear medicine;

- (ii)** the provision of medical and outpatient services, including in-person or remote medical consultations, outpatient procedures, outpatient procedures with resources for the performance of surgical procedures, complementary examinations, and the administration of medications, to private patients or through accredited companies, insurance companies, medical-hospital assistance entities, or other healthcare funding arrangements;
- (iii)** the performance of activities related to: (a) the testing of foods and substances for the purpose of assessing risks to humans; (b) the importation, for own use, of medical-hospital equipment, diagnostic kits and related items in general; (c) the preparation, editing, publication and distribution of newspapers, books, magazines, journals and other written media intended for scientific dissemination or for activities within the scope of the Company's operations; (d) the granting and administration of business franchises, including advertising and promotion funds, workforce training and selection, and the recommendation of suppliers of equipment and research materials, among others; (e) healthcare consulting and advisory services; (f) diagnostic and therapeutic complementary services; (g) learning programs and in-person and remote management training courses, exclusively in the medical field; (h) professional development field services for physicians, nurses and other professionals related to such activities, and the provision of means for scientific research and investigation; (i) business management consulting activities, exclusively in the medical field; (j) maintenance and repair of electro-medical and electro-therapeutic devices and irradiation equipment; (k) outpatient medical activities with resources for the performance of complementary examinations; (l) clinical research activities related to experimental research and development in physical and natural sciences, exclusively in the medical field; (m) psychology and psychoanalysis activities, in conjunction with the medical field; (n) nutritionist activities, in conjunction with the medical field; (o) physiotherapy activities, in conjunction with the medical field; and (p) nursing activities, in conjunction with the medical field;
- (iv)** the performance of the following activities, exclusively in the medical field: (a) the development and licensing of customizable and non-customizable computer programs; (b) the development of custom-made computer programs; and (c) technical support, maintenance and other information technology services;
- (v)** the provision of hospital care services;
- (vi)** prestar the provision of integrated patient care services through home-based medical and paramedical assistance, as well as consulting activities to support healthcare management, exclusively in the medical field;

(vii) the provision of: (i) speech therapy activities; (ii) occupational therapy activities; (iii) psychosocial care center activities; (iv) psychosocial and healthcare assistance activities for individuals with mental disorders, intellectual disabilities and chemical dependency, and similar groups not previously specified; and (v) social assistance services without accommodation; (viii) other service activities primarily rendered to companies not previously specified, exclusively in the medical field; and (ix) participation in other companies, whether corporate or non-corporate, in connection with medical activities, as a partner, quota holder or shareholder.

FHPJ: FHPJ is a limited liability company, headquartered in the City of Ribeirão Preto, State of São Paulo, at Rua Visconde de Inhaúma, No. 1,546, Higienópolis, ZIP Code 14025-100, enrolled with the Brazilian Corporate Taxpayer Registry (CNPJ/MF) under No. 00.750.852/0001-04. FHPJ's corporate purpose is the provision of clinical and pathological analysis services.

Aliança: Aliança is a limited liability company, headquartered in the City of Maringá, State of Paraná, at Rua Conselheiro Tobias, No. 57, Zona 04, ZIP Code 87014-270, enrolled with the Brazilian Corporate Taxpayer Registry (CNPJ/MF) under No. 08.284.269/0001-59. Aliança's corporate purpose includes: (i) the provision of molecular diagnostic services in humans and small- and large-size animals; and (ii) the conduct of research, development, production and commercialization of diagnostic kits and vaccines.

Institute of Hematology: The Institute of Hematology is a limited liability company, headquartered in the City of São José do Rio Preto, State of São Paulo, at Rua Conselheiro Tobias, No. 57, Zona 04, ZIP Code 87014-270, enrolled with the Brazilian Corporate Taxpayer Registry (CNPJ/MF) under No. 59.846.154/0001-41. The Institute of Hematology's corporate purpose is the provision of medical care services, laboratory examinations, and human vaccination and immunization services.

2. Descrição e Propósito da Operação

Proposed Transaction: The transaction consists of the merger into the Company of the following wholly-owned subsidiaries: **(i)** FHPJ; **(ii)** Aliança; and **(iii)** the Institute of Hematology. The Mergers involve the transfer of the entire net equity of the Merged Companies to the Company, which shall universally succeed them in all of their assets, rights and obligations, resulting in the extinction of the Merged Companies, pursuant to Article 227 of Law No. 6,404/1976 (the "Brazilian Corporations Law") and Article 1,116 of Law No. 10,406/2002 (the "**Brazilian Civil Code**"), as applicable.

Valuation Criterion: The criterion adopted for the valuation of the net assets of the Merged Companies to be absorbed by the Company shall be the book net equity value, determined in accordance with accounting practices adopted in Brazil, as of the reference date of December 31, 2025, based on the balance sheets prepared by the management of the Merged Companies on such date and specifically for this purpose.

Bylaws and Replacement of Equity Interests: The Company's Bylaws will not be amended as a result of the Mergers, nor will any shares of the Company be issued in substitution for the quotas issued by the Merged Companies.

Rights of the Company's Shares: The rights (or political and economic rights) attached to the shares issued by the Company will not undergo any change as a result of the Mergers.

Withdrawal Rights and Valuation pursuant to Article 264: Considering that the quotas issued by the Merged Companies are fully held by the Company, no exercise of withdrawal rights will arise as a result of the Mergers. The Company's shareholders will not be entitled to withdrawal rights in connection with the Mergers, pursuant to the Brazilian Corporations Law. The valuation referred to in Article 264 of the Brazilian Corporations Law is waived, as there are no shareholders in the Merged Companies other than the Company.

Conditions: The effectiveness of the Mergers is subject to: **(i)** approval by the Company, in its capacity as the sole quotaholder of the Merged Companies, and by the Company's shareholders, at a General Shareholders' Meeting, as applicable, of: (a) the Protocols and Justifications; (b) the ratification of the appointment and engagement of Apsis Consultoria e Avaliações Ltda., as an independent specialized firm responsible for preparing the valuation reports of the net assets of the Merged Companies to be absorbed by the Company in connection with the Mergers; (c) the valuation reports; (d) the Mergers; and (e) the authorization granted to the Managements of the Company and of the Merged Companies to carry out all acts necessary for the implementation of the Mergers; and **(ii)** verification by the Company's Board of Directors of the fulfillment of the condition precedent with a fixed term, so that the effectiveness and consummation of the Mergers occur on May 4, 2026, which date shall be considered the effective date of the Mergers.

3. Main Benefits, Costs and Risks of the Transaction

The Mergers are in the best interests of the Company, the Merged Companies, and their respective shareholders, as they seek to promote the simplification of the Group's corporate structure, with the consequent optimization and reduction of operating costs, the elimination of redundancies and inefficiencies in the efficient allocation of resources and personnel, as well as to unlock value drivers associated with the management and organization of the Company and the Merged Companies.

The Company's Management estimates that the total costs and expenses for carrying out the Mergers will amount to approximately R\$331,000.00 (three hundred and thirty-one thousand Brazilian reais), which include costs related to valuations, legal counsel, other advisory services for the implementation of the Mergers, publications and other related expenses. The Company clarifies that the estimated amount may not necessarily be fully incurred.

In the context of the Mergers, the Merged Companies will be extinguished, and the Company will succeed the Merged Companies in all of their rights and obligations. Other than the aforementioned succession risk, the Company does not foresee any material risks to the implementation of the Mergers, beyond those

customarily associated with the ordinary course of business of the companies involved and consistent with their size and operations. Risk factors related to the activities of all companies involved are already reflected in the Company's Reference Form.

4. Criteria for Determining the Exchange Ratio

Not applicable, given that all quotas issued by the Merged Companies are fully held by the Company. Accordingly, the transaction will not result in the issuance of new shares by the Company or any change to its capital stock.

5. Approval by Brazilian or Foreign Authorities

Not applicable, since the Mergers will not be subject to review or approval by any authority, whether in Brazil or abroad.

6. Applicability of Withdrawal Rights and Reimbursement Amount

Not applicable, given that (i) the Mergers will not give rise to withdrawal rights for the Company's shareholders, pursuant to the Brazilian Corporations Law, and (ii) the Company is the sole quotaholder of the Merged Companies

7. Other Relevant Information

The Company's Board of Directors approved the convening of the Ordinary and Extraordinary General Shareholders' Meeting to approve, among other matters, the Protocols and Justifications and the Corporate Reorganization. The documents required for the exercise of voting rights are available at the Company's headquarters, on the Company's Investor Relations website (www.dasa3.com.br), on the website of B3 S.A. – Brasil, Bolsa, Balcão (www.b3.com.br), and on the website of the Brazilian Securities and Exchange Commission (CVM) (www.cvm.gov.br), and may be consulted by the Company's shareholders in accordance with the applicable regulations.

The Company will keep its shareholders and the market duly informed of the developments of the transaction that is the subject matter of this Material Fact, including pursuant to the terms of CVM Resolution No. 78/22.

Barueri, March 27, 2026.

Dulce Pugliese de Godoy Bueno
President of the Board of Directors